These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27033349)

  • 21. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine.
    Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F
    Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hybrid liposomal PEGylated calix[4]arene systems as drug delivery platforms for curcumin.
    Drakalska E; Momekova D; Manolova Y; Budurova D; Momekov G; Genova M; Antonov L; Lambov N; Rangelov S
    Int J Pharm; 2014 Sep; 472(1-2):165-74. PubMed ID: 24954662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
    Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
    J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
    Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
    J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro determination of the efficacy of scorpion venoms as anti-cancer agents against colorectal cancer cells: a nano-liposomal delivery approach.
    Al-Asmari AK; Ullah Z; Al Balowi A; Islam M
    Int J Nanomedicine; 2017; 12():559-574. PubMed ID: 28144138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
    Nagao A; Abu Lila AS; Ishida T; Kiwada H
    Int J Pharm; 2013 Jan; 441(1-2):395-401. PubMed ID: 23174409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Curcumin loaded pH-sensitive hybrid lipid/block copolymer nanosized drug delivery systems.
    Jelezova I; Drakalska E; Momekova D; Shalimova N; Momekov G; Konstantinov S; Rangelov S; Pispas S
    Eur J Pharm Sci; 2015 Oct; 78():67-78. PubMed ID: 26159739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU.
    He RX; Ye X; Li R; Chen W; Ge T; Huang TQ; Nie XJ; Chen HJ; Peng DY; Chen WD
    J Liposome Res; 2017 Jun; 27(2):161-170. PubMed ID: 27184460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel nanostructural photosensitizers for photodynamic therapy: in vitro studies.
    Nawalany K; Rusin A; Kepczynski M; Filipczak P; Kumorek M; Kozik B; Weitman H; Ehrenberg B; Krawczyk Z; Nowakowska M
    Int J Pharm; 2012 Jul; 430(1-2):129-40. PubMed ID: 22525077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
    Krieger ML; Eckstein N; Schneider V; Koch M; Royer HD; Jaehde U; Bendas G
    Int J Pharm; 2010 Apr; 389(1-2):10-7. PubMed ID: 20060458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
    Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
    Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation the Anti-Cancer Effect of PEGylated Nano-Niosomal Gingerol, on Breast Cancer Cell lines (T47D), In-Vitro.
    Behroozeh A; Mazloumi Tabrizi M; Kazemi SM; Choupani E; Kabiri N; Ilbeigi D; Heidari Nasab A; Akbarzadeh Khiyavi A; Seif Kurdi A
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):645-648. PubMed ID: 29580033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional liposomes in the cancer-targeted drug delivery.
    Tila D; Ghasemi S; Yazdani-Arazi SN; Ghanbarzadeh S
    J Biomater Appl; 2015 Jul; 30(1):3-16. PubMed ID: 25823898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
    Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
    Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.